Your Top 100 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
Ann‐Lii Cheng, S. Qin, Masafumi Ikeda, Peter R. Galle, Michel Pierre Ducreux, Andrew Xiuxuan Zhu and 14 more
- Rank
- 67 of 4,622
- Percentile
- top 1.5%
- Where
- Annals of Oncology, 2019
- Citations
- 194
From the 2019 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.